DISPOSITION OF ORAL LISURIDE IN PARKINSONS-DISEASE

被引:11
作者
BURNS, RS
GOPINATHAN, G
HUMPEL, M
DOROW, R
CALNE, DB
机构
[1] VET ADM HOSP,NEW YORK,NY
[2] SCHERING AG,DEPT PHARMACOKINET & NEUROENDOCRINOL NEUROPSYCHOPHARMACOL,BERLIN,FED REP GER
[3] UNIV BRITISH COLUMBIA,HLTH SCI CTR HOSP,VANCOUVER V6T 1W5,BC,CANADA
关键词
D O I
10.1038/clpt.1984.76
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:548 / 556
页数:9
相关论文
共 34 条
  • [1] DIRECT BINDING OF LISURIDE-H-3 TO ADRENERGIC AND SEROTONERGIC RECEPTORS
    BATTAGLIA, G
    TITELER, M
    [J]. LIFE SCIENCES, 1981, 29 (09) : 909 - 916
  • [2] SUPPRESSION OF PROLACTIN SECRETION BY LISURIDE THROUGHOUT THE MENSTRUAL-CYCLE AND IN HYPERPROLACTINEMIC MENSTRUAL DISORDERS
    BOHNET, HG
    HANKER, JP
    HOROWSKI, R
    WICKINGS, EJ
    SCHNEIDER, HPG
    [J]. ACTA ENDOCRINOLOGICA, 1979, 92 (01): : 8 - 19
  • [3] BRADLEY SE, 1963, HANDBOOK PHYSIOLOG 2, V2, P1387
  • [4] BURNS RS, 1981, APOMORPHINE OTHER DO, V2
  • [5] DOROW R, 1983, LISURIDE OTHER DOPAM
  • [6] BINDING OF LISURIDE-H-3 HYDROGEN MALEATE TO STRIATAL MEMBRANES OF RAT-BRAIN
    FUJITA, N
    SAITO, K
    YONEHARA, N
    WATANABE, Y
    YOSHIDA, H
    [J]. LIFE SCIENCES, 1979, 25 (11) : 969 - 974
  • [7] FUJITA N, 1978, NEUROPHARMACOLOGY, V17, P1089
  • [8] FUXE K, 1979, DOPAMINERGIC ERGOT D
  • [9] GIBALDI M, 1975, PHARMACOKINETICS
  • [10] GOLDSTEIN M, 1980, ERGOT COMPOUNDS BRAI